世界胰腺癌日是每年的11月第3個(gè)星期四，旨在提高公眾對(duì)胰腺癌的認(rèn)識(shí)和關(guān)注。胰腺癌是一種發(fā)生在胰腺細(xì)胞中的惡性腫瘤，胰腺位于胃后方，負(fù)責(zé)分泌消化酶和調(diào)節(jié)血糖水平的激素。胰腺癌的病因尚未完全明確，但已知多個(gè)風(fēng)險(xiǎn)因素，包括吸煙、肥胖、糖尿病、慢性胰腺炎以及家族病史等。胰腺癌通常預(yù)后較差，5年存活率不足10%，早期癥狀不典型，往往在發(fā)現(xiàn)時(shí)已處于中晚期，因此被稱為“癌中之王”。胰腺癌的發(fā)病率在全球范圍內(nèi)居惡性腫瘤的第13位，死亡率居腫瘤相關(guān)死亡的第8位。
胰腺癌主要分為兩種類型：外分泌性胰腺癌（約占所有病例的95%）和內(nèi)分泌或胰島細(xì)胞瘤（也稱為胰島素細(xì)胞瘤），后者較為罕見。胰腺癌的早期癥狀不典型，可能包括上腹部不適或隱痛、消瘦、乏力等，容易被誤認(rèn)為是其他消化系統(tǒng)疾病。因此，加強(qiáng)胰腺癌早期診斷和治療，對(duì)于改善胰腺癌患者的預(yù)后具有重要意義。
胰腺癌的治療手段主要包括手術(shù)切除、化療、放療、免疫和靶向治療等。免疫治療是近年來胰腺癌治療的新焦點(diǎn)。目前，已有多個(gè)靶向不同靶點(diǎn)，如IGF-lR、EGFR、HER2、VEGF、CTLA-4、PD-1的抗體藥物處于臨床研究階段 [1]。
為更好的協(xié)助您進(jìn)行胰腺癌相關(guān)機(jī)制研究和藥物開發(fā)，華美生物特整理了胰腺癌研究相關(guān)熱門靶點(diǎn)及對(duì)應(yīng)產(chǎn)品，供您參考。
胰腺癌藥物研究靶點(diǎn)
- ACSL4
- AKT1
- ANXA1
- AXL
- BAG3
- CCN2
- CCR8
- CD274
- CD276
- CD3D
- CD40
- CD47
- CD8A
- CDCP1
- CDH17
- CEACAM1
- CEACAM5
- CEACAM6
- CLDN18
- CNTN4
- CSF1R
- CTLA4
- DCLK1
- DKK3
- EGFR
- ENO1
- EPHA2
- ERBB2
- ERBB3
- F3
- FOLR1
- FTH1
- GAPDH
- GCC1
- GPC1
- GPX4
- HAVCR2
- HGF
- HMOX1
- ICOS
- IER3
- IGF1R
- IL1A
- KEAP1
- LOXL2
- MELTF
- MMP9
- MSLN
- MSTN
- MTOR
- MUC1
- MUC16
- NCOA4
- NECTIN4
- NFE2L2
- NFKB1
- NT5E
- PDCD1
- SLC3A2
- SLC44A4
- SLC7A11
- TAA1
- TACSTD2
- TF
- TFRC
- TIGIT
- TNF
- TNFRSF10B
- TNFRSF9
- TP53
- VEGFA
- VSIR
- ZG16B
胰腺癌研究相關(guān)產(chǎn)品推薦
● 重組蛋白
CSB-MP004936HU1
Human CD40 protein hFc tag (CSB-MP004936HU1) captured on COOH chip can bind Human CD40L protein hFc and Flag tag (CSB-MP004937HU3) with an affinity constant of 2.06 nM as detected by LSPR Assay.
CSB-MP005498HU(A5)
-AC1.jpg)
Measured by its binding ability in a functional ELISA. Immobilized human CLDN18.2 (CSB-MP005498HU(A5)) at 5 μg/ml can bind anti-CLDN18.2 recombinant Monoclonal Antibody (CSB-RA005498A1HU), the the EC50 is 5.225-9.256 ng/ml.
CSB-MP006163HU1
Measured by its binding ability in a functional ELISA. Immobilized CD152 at 2 μg/ml can bind Anti-CD152 rabbit monoclonal antibody (CSB-RA213310A0HU), the EC50 of human CD152 protein is 27.14-34.82 ng/ml
CSB-MP704410HU3c7
Measured by its binding ability in a functional ELISA. Immobilized MUC16 at 10 μg/ml can bind MSLN (CSB-MP015044HUc9), the EC50 is 460.7-662.2 ng/ml.
CSB-MP619964HU1
Measured by its binding ability in a functional ELISA. Immobilized PD-1 at 2 μg/ml can bind Anti-PD-1 recombinant antibody, the EC50 of human PD-1 protein is 6.087-7.854 ng/ml.
CSB-MP023072HU2
Measured by its binding ability in a functional ELISA. Immobilized Human TROP2 at 2 μgg/mL can bind Anti-TROP2 recombinant antibody (CSB-RA023072MA1HU), the EC50 is 0.9108-1.640 ng/mL.
CSB-MP023984HU1
Measured by its binding ability in a functional ELISA. Immobilized TNFRSF9 at 2 μg/ml can bind TNFSF9 (CSB-MP023997HU1), the EC50 is 1.011-2.429 ng/mL.
CSB-MP836195HU
Measured by its binding ability in a functional ELISA. Immobilized Human ZG16B at 2 μg/ml can bind Anti-ZG16B recombinant antibody (CSB-RA836195MA1HU), the EC50 is 24.13-46.04 ng/mL.
● 穩(wěn)定細(xì)胞株
CHOK1/Human CCR8 Stable Cell Line
CSB-SC004847HU2
Untransfected CHO-K1 cells (green line) and transfected Human CCR8 CHO-K1 stable cells (red line) were stained with anti-CCR8 antibody (CSB-RA004847A1HU) (2μg/1*106 cells), washed and then followed by FITC-conjugated anti-Human IgG Fc antibody and analyzed with flow cytometry.
CT26/Human CCR8 Stable Cell Line
CSB-SC004847HU3
Untransfected CT26 cells (green line) and transfected Human CCR8 CT26 Stable cells (red line) were stained with anti-CCR8 antibody (2μg/1*106 cells), washed and then followed by FITC-conjugated anti-Human IgG Fc antibody and analyzed with flow cytometry.
CHOK1/Mouse CCR8 Stable Cell Line
CSB-SC004847MO
Untransfected CHO-K1 cells (green line) and transfected Mouse CCR8 CHO-K1 Stable cells (red line) were stained with anti-Mouse CD198-PE antibody (2μg/1*106 cells) and analyzed with flow cytometry.
HEK293T/Human CDH17 Stable Cell Line
CSB-SC613267HU2
Untransfected HEK293T cells (green line) and transfected Human CDH17 HEK293T stable cells (red line) were stained with anti-CDH17 antibody (CSB-RA613267MA1HU) (2μg/1*106), washed and then followed by FITC-conjugated anti-Human IgG Fc antibody and analyzed with flow cytometry.
● 抗體
CSB-RA006163MA1HU
Tested Applications：
ELISA, WB, IF, FC
CSB-RA159341A0HU
Tested Applications：
ELISA, WB, IHC, IF, FC
CSB-RA009232MA1HU
Tested Applications：
ELISA, WB, IHC, IF, FC
CSB-RA024077MA1HU
Tested Applications：
ELISA, WB, IF, FC
| 產(chǎn)品名稱 | 貨號(hào) | 靶點(diǎn) | 反應(yīng)種屬 | 應(yīng)用范圍 |
|---|---|---|---|---|
| Phospho-AKT1 (T450) Recombinant Monoclonal Antibody | CSB-RA001553A450phHU | AKT1 | Human | ELISA, WB |
| Phospho-AKT1 (Ser473) Recombinant Monoclonal Antibody | CSB-RA001553A473phHU | AKT1 | Human | ELISA, WB, IHC, IF, IP |
| AKT1 Recombinant Monoclonal Antibody | CSB-RA917625A0HU | AKT1 | Human, Mouse, Rat | ELISA, WB, IHC, IF |
| ANXA1 Recombinant Monoclonal Antibody | CSB-RA001836MA1HU | ANXA1 | Human | ELISA, IHC, FC |
| BAG3 Recombinant Monoclonal Antibody | CSB-RA002531A0HU | BAG3 | Human | ELISA, WB, IHC |
| CCR8 Recombinant Monoclonal Antibody | CSB-RA004847A1HU | CCR8 | Human | FC |
| CCR8 Recombinant Monoclonal Antibody | CSB-RA004847MA3HU | CCR8 | Human | FC |
| CCR8 Recombinant Monoclonal Antibody | CSB-RA004847MA2HU | CCR8 | Human | FC |
| CCR8 Recombinant Monoclonal Antibody | CSB-RA004847MA4HU | CCR8 | Human | FC |
| CD274 Recombinant Monoclonal Antibody | CSB-RA977797A0HU | CD274 | Human | ELISA, WB, IHC |
| CD274 Recombinant Monoclonal Antibody | CSB-RA878942MA1HU | CD274 | Human | ELISA, IHC, FC |
| CD40 Recombinant Monoclonal Antibody | CSB-RA004936MA1HU | CD40 | Human | ELISA, IF, FC |
| CD47 Recombinant Monoclonal Antibody | CSB-RA802124A0HU | CD47 | Human | ELISA, WB, IHC, IF |
| CD8A Recombinant Monoclonal Antibody | CSB-RA934881A0HU | CD8A | Human | ELISA, WB, IHC, IP |
| CDCP1 Recombinant Monoclonal Antibody | CSB-RA884474MA1HU | CDCP1 | Human, Mouse, Macaca fascicularis | ELISA |
| CDH17 Recombinant Monoclonal Antibody | CSB-RA613267MA1HU | CDH17 | Human | ELISA，F(xiàn)C |
| CEACAM1 Recombinant Monoclonal Antibody | CSB-RA147192A0HU | CEACAM1 | Human | ELISA, IHC |
| CEACAM5 Recombinant Monoclonal Antibody | CSB-RA005165MA3HU | CEACAM5 | Human | ELISA, IF, FC |
| CEACAM5 Recombinant Monoclonal Antibody | CSB-RA005165MA1HU | CEACAM5 | Human | ELISA |
| CLDN18 Recombinant Monoclonal Antibody | CSB-RA005498A2HU | CLDN18 | Human | ELISA, FC |
● ELISA試劑盒
| 產(chǎn)品名稱 | 樣本類型 | 檢測(cè)范圍 | 貨號(hào) |
|---|---|---|---|
| Human RAC-alpha serine/threonine-protein kinase(AKT1) ELISA kit | serum, plasma, cell lysates | 0.312 ng/mL-20 ng/mL | CSB-EL001553HU |
| Mouse Annexin A1(ANXA1) ELISA kit | serum, plasma, tissue homogenates | 1.37ng/ml - 1000ng/ml | CSB-EL001836MO |
| Human Annexin Ⅰ(ANX-Ⅰ) ELISA Kit | serum, plasma, tissue homogenates | 0.312 ng/mL-20 ng/mL | CSB-E12155h |
| Human Tyrosine-protein kinase receptor UFO (AXL) ELISA Kit | serum, plasma, tissue homogenates | 31.25 pg/mL-2000 pg/mL | CSB-EL002476HU |
| Mouse Tyrosine-protein kinase receptor UFO(AXL) ELISA Kit | serum, plasma, tissue homogenates. | 31.25 pg/ml-2000 pg/ml | CSB-EL002476MO |
| Human Programmed Death Ligand-1(PD-L1/CD274) ELISA Kit | serum, plasma, tissue homogenates, cell lysates | 15.6 pg/mL-1000 pg/mL | CSB-E13644h |
| Mouse Programmed cell death 1 ligand 1(CD274) ELISA kit | serum, plasma, tissue homogenates | 31.25 pg/mL-2000 pg/mL | CSB-EL004911MO |
| Human Soluble CD276,sCD276/sB7-H3 ELISA Kit | serum, plasma, urine, cell culture supernates | 3.12 ng/mL-200 ng/mL | CSB-E14285h |
| Mouse Tumor necrosis factor receptor superfamily member 5(CD40) ELISA kit | Request Information | CSB-EL004936MO | |
| Human Leukocyte surface antigen CD47(CD47) ELISA kit | serum, plasma, urine, tissue homogenates | 3.12 pg/mL-200 pg/mL | CSB-EL004940HU |
| Mouse Leukocyte surface antigen CD47(CD47) ELISA kit | serum, plasma,tissue homogenates | 15.6 pg/mL-1000 pg/mL | CSB-EL004940MO |
| Human Cluster of differentiation 8,CD8 ELISA Kit | serum, plasma, cell culture supernates, tissue homogenates | 62.5 U/mL-4000 U/mL | CSB-E12707h |
| Human Carcinoembryonic antigen-related cell adhesion molecule 1(CEACAM1) ELISA kit | serum, plasma, tissue homogenates | 0.78 ng/mL-50 ng/mL | CSB-EL005157HU |
| Human carcinoembryonic antigen,CEA ELISA Kit | serum, plasma, tissue homogenates | 5 ng/mL-120 ng/mL | CSB-E04767h |
| Mouse carcinoembryonic antign,CEA ELISA Kit | serum, plasma, tissue homogenates | 62.5 pg/mL-4000 pg/mL | CSB-E13925m |
| Human Carcinoembryonic antigen-related cell adhesion molecule 6(CEACAM6) ELISA kit | serum, plasma, tissue homogenates | 0.83 ng/mL-20 ng/mL | CSB-EL005166HU |
| Human Macrophage Colony-Stimulating Factor Receptor,M-CSFR ELISA Kit | serum, plasma, tissue homogenates | 0.156 ng/mL-10 ng/mL | CSB-E10012h |
| Rat Macrophage colony-stimulating factor 1 receptor(CSF1R) ELISA kit | serum, plasma, tissue homogenates | 0.312 ng/mL-20 ng/mL | CSB-EL006044RA |
| Human cytotoxic T lymphocyte associated antigen 4,CTLA-4 ELISA Kit | serum, plasma, tissue homogenates | 125 pg/mL-8000 pg/mL | CSB-E09171h |
| Mouse cytotoxic T lymphocyte associated antigen 4,CTLA-4 ELISA Kit | serum, plasma, tissue homogenates | 0.312 ng/mL-20 ng/mL | CSB-E13637m |
藥物研發(fā)解決方案
特色服務(wù)項(xiàng)目
專家講堂
參考文獻(xiàn)
[1] Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities. Cancers (Basel), 2021.
